Global Small Molecule Cancer Drugs Market – Insights
Cancer is characterized by uncontrolled cell growth, which leads to formation of tumor. The tumor can further progress to other body parts. Although the major cause of cancer is genetic mutation, other factors such as environmental, lifestyle, or hereditary can also lead to the disease. Cancer is classified into four categories based on its origin – 1) Carcinoma (begins in skin or tissue) 2) Sarcoma (begins in connective tissues) 3) Lymphoma (begins in lymphatic system), and 4) Leukemia (begins in blood).
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-sample/2754
Increasing approval of small molecule cancer drugs to augment growth of the global small molecule cancer drugs market
Major regulatory bodies are focused on approval of novel small molecule cancer drugs, which is expected to propel growth of the global small molecule cancer drugs market over the forecast period. For instance, in May 2019, the U.S. Food & Drug Administration (FDA) approved Novartis AG’s Piqray – a drug used in combination with fluvestrant for the treatment of HR/HER2- PIK3CA mutated advanced breast cancer. Similarly, in April 2019, the U.S. FDA approved Balversa (erdafitinib) (Janssen Pharmaceutica) for the treatment of FGFR3 or FGFR2 mutated, locally advanced urothelial carcinoma.
Adverse effects of small molecule cancer drugs to hinder growth of the market
Use of small molecule cancer drugs is associated with several side effects, depending on the type of cancer and the overall health of the patient. Major side effects include, muscle pain, headache, nausea, vomiting, fatigue, mouth sores, diarrhea, throat sores, and constipation. Moreover, small molecule cancer drugs also adversely impact healthy cells, thereby leading to malfunction in blood cells regeneration process. These factors are expected to hinder growth of the global small molecule cancer drugs market.
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2754
North America to hold dominant position in the market
On the basis of region, the global small molecule cancer drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to account for the largest market share over the forecast period. This is attributed to increasing investment in R&D in cancer drugs. For instance, in June 2019, American Cancer Society partnered with Ovarian Cancer Research Alliance to fund research activities related to detection, treatment, and prevention of ovarian cancer. The partnership is focused on raising funds for R&D of drugs for ovarian cancer.
Global Small Molecule Cancer Drugs Market: Competitive Landscape
Key players in the global small molecule cancer drugs market are focused on adopting M&A strategies to expand their product portfolio. For instance, in June 2019, Pfizer Inc., a pharmaceutical company, acquired Array Biopharma, a drug developer company. The acquisition gave Pfizer access to Array Biopharma’s product portfolio that included drugs for the treatment of skin cancer and combination of drugs (Braftovi and Mektovi) used for the treatment of last-stage colorectal cancer.
Major players operating in the global small molecule cancer drugs market include Janssen Research and Development LLC, Novartis AG, Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Co., Pfizer Inc., SANOFI AVENTIS US LLC, Baxter Healthcare Corp., Emcure Pharmaceuticals Ltd., AstraZeneca, Kyowa Kirin Inc., and HQ Specialty Pharma Corp.
Request to download and view full ToC: https://www.coherentmarketinsights.com/ongoing-insight/toc/2754
Global Small Molecule Cancer Drugs Market Taxonomy
The global small molecule cancer drugs market is segmented on the basis of drug class, route of administration, distribution channel, and region.
By Drug Class
- Alkylating Agents
- Plant Alkaloids
- Antitumor Antibiotics
- Antimetabolites
- Topoisomerase Inhibitors
- Others
By Route of Administration
- Oral
- Injectable
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Other Related Reports:
Esophageal Cancer Drugs Market scenario 2020 – Competitive Analysis, Segmentation by 2027
Stomach Cancer Drugs Market scenario 2020 – Competitive Analysis, Segmentation by 2026
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
